Enpatoran

Commentary around Merck KGaA's enpatoran is challenging the framing of the WILLOW trial results, arguing the drug was not proven ineffective but that the trial's chosen endpoint failed to capture the treatment effect. The piece says the outcome measure, not the therapy itself, is what fell short, reigniting debate over how lupus clinical trials are designed and judged.